455 related articles for article (PubMed ID: 15838331)
1. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
[TBL] [Abstract][Full Text] [Related]
2. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
3. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.
Daull P; Lepage R; Benrezzak O; Cayer J; Beaudoin M; Belleville K; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
Drug Chem Toxicol; 2006; 29(2):183-202. PubMed ID: 16707327
[TBL] [Abstract][Full Text] [Related]
4. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
5. Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats.
Battistini B; Ayach B; Molez S; Blouin A; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():363S-366S. PubMed ID: 12193123
[TBL] [Abstract][Full Text] [Related]
6. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
[TBL] [Abstract][Full Text] [Related]
7. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats.
Daull P; Blouin A; Belleville K; Beaudoin M; Arsenault D; Leonard H; Sirois P; Nantel F; Jeng AY; Battistini B
Exp Biol Med (Maywood); 2006 Jun; 231(6):830-3. PubMed ID: 16741007
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP.
Pu Q; Brassard P; Javeshghani DM; Iglarz M; Webb RL; Amiri F; Schiffrin EL
J Hypertens; 2008 Feb; 26(2):322-33. PubMed ID: 18192847
[TBL] [Abstract][Full Text] [Related]
10. Effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, CGS 30440, on blood pressure and cardiac hypertrophy in spontaneously hypertensive rats.
Webb RL; Abramson ML; Beil ME; Odorico LM; Chatelain RE
J Cardiovasc Pharmacol; 1997 Nov; 30(5):632-42. PubMed ID: 9388046
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system.
Iyer SN; Ferrario CM; Chappell MC
Hypertension; 1998 Jan; 31(1 Pt 2):356-61. PubMed ID: 9453328
[TBL] [Abstract][Full Text] [Related]
12. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
[TBL] [Abstract][Full Text] [Related]
14. Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension.
Maniu CV; Meyer DM; Redfield MM
Hypertension; 2002 Oct; 40(4):528-34. PubMed ID: 12364358
[TBL] [Abstract][Full Text] [Related]
15. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
French JF; Anderson BA; Downs TR; Dage RC
J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
[TBL] [Abstract][Full Text] [Related]
17. Effect of dual angiotensin converting enzyme/neutral endopeptidase inhibition, angiotensin converting enzyme inhibition, or AT1 antagonism on coronary microvasculature in spontaneously hypertensive rats.
Pu Q; Larouche I; Schiffrin EL
Am J Hypertens; 2003 Nov; 16(11 Pt 1):931-7. PubMed ID: 14573331
[TBL] [Abstract][Full Text] [Related]
18. Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats.
Pham I; Lévy B; Fournié-Zaluski MC; Poitevin P; Roques BP; Michel JB
Fundam Clin Pharmacol; 1995; 9(2):153-60. PubMed ID: 7628828
[TBL] [Abstract][Full Text] [Related]
19. Role of the endothelin system in secondary pulmonary hypertension related to air embolism: lessons learned from testing four classes of endothelin blockers in a rat model.
Battistini B; Verreault M; Ayach B; Blouin A; Cernacek P; Jeng AY; Wessale J; Opgenorth T; Tsang J
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S386-9. PubMed ID: 15838327
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of both neutral endopeptidase and endothelin-converting enzyme by SLV306 reduces proteinuria and urinary albumin excretion in diabetic rats.
Thöne-Reinke C; Simon K; Richter CM; Godes M; Neumayer HH; Thormählen D; Hocher B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S76-9. PubMed ID: 15838365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
